in the last two years, the company has been able to develop new therapeutic agents and have been able to improve survival in patients with metastatic prostate cancer. in this article, we will provide an update on our clinical programs and anticipate anticipated milestones through the end of this year and into 2016. we will also discuss our financial results for the second quarter and we will conclude the call with questions.